Alpharetta-based pharmaceutical firm, Alimera Sciences, Inc., specializes in the development and commercialization of ophthalmic pharmaceuticals. Known for its flagship product, ILUVIEN – a revolutionary implant offering treatment for diabetic macular edema (DME), which causes severe vision loss and blindness – the company operates across both domestic and international markets, including Operating Cost segments. Alimera's product is also a preventative measure for recurrent non-infectious uveitis which affects the posterior segment of the eye. The organization offers its products to an extensive network of physicians' offices, clinics, pharmacies, and hospitals via direct sales or distributor partnerships. Its recent collaboration agreement with EyePoint Pharmaceuticals US, Inc. aims to provide further treatment options for eye diseases like DME, by developing innovative insert technology to deliver corticosteroids to the back of the eye. Alimera Sciences, Inc. was established in 2003 and continues to make strides in offering effective, innovative ophthalmic pharmaceuticals with its headquarters in Georgia.